The United States of America As Represented by the Department of Health

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Sanyo-kokusaku Pulp Co., Ltd.

Stichting Rega Vzw

The Government of the United States of America

Stichting Rega Vzw (rega)

Samuel Broder

Hiroaki Mitsuya

Robert Yarchoan

Erik D De Clercq

Piet A Herdewijn

Jan M Balzarini

Jay A Berzofsky

Hidetoshi Yoshioka

Jiri Zemlicka

Marjorie Robert-Guroff

Kunichika Murakami

Eiji Kojima

Takahiro Okazaki

Takuma Shirasaka

Andrew Catanzaro

Shuzo Matsushita

James T Snyder, Ii

Seiji Hayashi

Shashikant Phadtare

The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.

Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus

A method for inhibiting intracellular replication of HIV in an HIV-infected individual comprising contacting the HIV reverse transcriptase in the HIV-infected cells with 2',3'-dideoxyadenosine-5'-triphosphate whose source is 2',3'-dideoxyadenosine or a pharmaceutically acceptable salt or prodrug thereof.

Method of inhibiting HIV replication with 2',3'-dideoxyadenosine

An anti-AIDS virus agent is disclosed, which is characterized in that it contains the 2',3'-dideoxypurinenucleosides represented by the chemical formula (I): ##STR1## as an effective ingredient.

Pharmaceutical composition containing

A preferred method and dosages for treatment of retrovirus-induced dementia by the administration of 2',3'-dideoxyinosine(ddI) is disclosed.

Treatment of retroviral induced dementia by administration of

A method for tearing retroviral infections including acquired immune deficiency syndrome (AIDS) with 2',3'-dideoxyinosine or 2',3'-dideoxyadenosine is disclosed. This antiviral effect is irreversible with 2',3'-dideoxyinosine and 2',3'-dideoxyadenosine but reversible with 2',3'-dideoxyguanosine.

Method of treating HIV with 2',3'-dideoxyinosine

The compound 2',3'-dideoxycytidinene has an antiviral effect against human immunodeficiency virus (HIV) and may therefore be used as a therapeutic agent for treating AIDS and related diseases.

Therapeutic application of dideoxycytidinene

A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeficiency virus (HIV) infection, with 2',3'-dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2',3'-dideoxyinosine to minimize certain side effects.

Treatment of human retroviral infections with 2',3'-dideoxyinosine alone

The present invention relates to a composition containing the compound 2', 3'-dideoxycytidinene which has an antiviral effect against human immunodeficiency virus (HIV) and may therefore be used as a therapeutic agent for the treatment of AIDS and AIDS related diseases.

Compounds which are active against retroviruses have the following formula

Pyrimidine and purine 1,2-butadiene-4-ols as anti-retroviral agents

Compositions containing 2',3'-dideoxycytidine and its triphosphates for use in treating retroviral infections including acquired immune deficiency syndrome (AIDS) are disclosed with preferred methods of treatment which provide protection against cytophatic effects of human immunodeficiency virus (HIV).

Antiviral compositions and methods

Compositions containing 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, and dideoxyguanosine and their triphosphates for use in treating retroviral infections including acquired immune deficiency syndrome (AIDS) are disclosed with preferred methods of treatment which provide protection against cytopathic effects of human immunodeficiency virus (HIV).

The present invention is an immortalized B-cell line which produces a human monoclonal antibody IgG-Kk which specifically binds to the envelope antigen of human T-cell leukemia virus Type 1 (HTLV-I). This monoclonal antibody is useful as a diagnostic reagent by binding to the antigen specifically expressed on the surface of HTLV producing cells. Furthermore, this monoclonal antibody is useful as a therapeutic reagent, in combination with complement, for the lysis of HTLV-1 producing cells.

Cell line producing human monoclonal antibody which binds to HTLV-I

This invention is an immortalized T-cell clone, designated ATH8, which is highly sensitive to the cytopathic effect of HTLV-III. The ATH8 T-cell clone is used in mass screening systems to rapidly and easily determine the in vitro capacity of new drugs or other agents to inactivate or inhibit HTLV-III or related cytopathic retroviruses.

Growing community of inventors

Bethesda, MD, United States of America

Samuel Broder